Oric Pharmaceuticals (NASDAQ:ORIC) Now Covered by Analysts at Evercore ISI

Evercore ISI assumed coverage on shares of Oric Pharmaceuticals (NASDAQ:ORIC) in a research note issued to investors on Thursday morning, Marketbeat Ratings reports. The firm issued an outperform rating and a $25.00 target price on the stock.

A number of other equities analysts have also commented on the stock. JPMorgan Chase & Co. lifted their price target on shares of Oric Pharmaceuticals from $17.00 to $20.00 and gave the stock an “overweight” rating in a report on Tuesday. Zacks Research upgraded Oric Pharmaceuticals to a “hold” rating in a research report on Tuesday, August 12th. Guggenheim started coverage on Oric Pharmaceuticals in a research note on Thursday, September 4th. They issued a “buy” rating and a $18.00 price target for the company. Wedbush reaffirmed an “outperform” rating and issued a $20.00 price objective on shares of Oric Pharmaceuticals in a research note on Friday, November 14th. Finally, Citigroup upped their target price on Oric Pharmaceuticals from $12.00 to $16.00 and gave the company a “buy” rating in a report on Monday. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $19.00.

Oric Pharmaceuticals Stock Performance

NASDAQ:ORIC opened at $11.48 on Thursday. The stock’s 50-day moving average is $12.28 and its 200-day moving average is $10.29. Oric Pharmaceuticals has a 1-year low of $3.90 and a 1-year high of $14.93. The stock has a market cap of $1.12 billion, a P/E ratio of -6.64 and a beta of 1.66.

Oric Pharmaceuticals (NASDAQ:ORIC) last posted its earnings results on Thursday, November 13th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.08. As a group, equities analysts forecast that Oric Pharmaceuticals will post -2.17 EPS for the current year.

Insider Activity at Oric Pharmaceuticals

In other Oric Pharmaceuticals news, CEO Jacob Chacko sold 37,461 shares of Oric Pharmaceuticals stock in a transaction that occurred on Monday, October 6th. The stock was sold at an average price of $12.32, for a total value of $461,519.52. Following the completion of the sale, the chief executive officer directly owned 531,419 shares in the company, valued at approximately $6,547,082.08. The trade was a 6.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Dominic Piscitelli sold 11,000 shares of the business’s stock in a transaction that occurred on Monday, October 6th. The shares were sold at an average price of $14.52, for a total value of $159,720.00. Following the completion of the transaction, the chief financial officer directly owned 48,317 shares in the company, valued at approximately $701,562.84. This trade represents a 18.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 261,000 shares of company stock valued at $3,024,703 in the last ninety days. 6.82% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Oric Pharmaceuticals

Large investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Oric Pharmaceuticals by 36.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,755 shares of the company’s stock valued at $45,000 after purchasing an additional 1,009 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Oric Pharmaceuticals by 2.9% in the 2nd quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 49,000 shares of the company’s stock valued at $497,000 after buying an additional 1,358 shares in the last quarter. ANTIPODES PARTNERS Ltd increased its position in Oric Pharmaceuticals by 35.9% in the 2nd quarter. ANTIPODES PARTNERS Ltd now owns 5,194 shares of the company’s stock valued at $53,000 after buying an additional 1,372 shares in the last quarter. ProShare Advisors LLC raised its stake in Oric Pharmaceuticals by 12.9% during the 3rd quarter. ProShare Advisors LLC now owns 13,383 shares of the company’s stock worth $161,000 after buying an additional 1,527 shares during the period. Finally, Woodline Partners LP boosted its holdings in Oric Pharmaceuticals by 0.9% in the third quarter. Woodline Partners LP now owns 246,534 shares of the company’s stock worth $2,958,000 after acquiring an additional 2,166 shares in the last quarter. 95.05% of the stock is currently owned by institutional investors and hedge funds.

About Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.